GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Calithera Biosciences Inc (OTCPK:CALA) » Definitions » 3-Year Dividend Growth Rate

Calithera Biosciences (Calithera Biosciences) 3-Year Dividend Growth Rate : 0.00% (As of Dec. 2022)


View and export this data going back to 2014. Start your Free Trial

What is Calithera Biosciences 3-Year Dividend Growth Rate?

Calithera Biosciences's Dividends per Share for the three months ended in Dec. 2022 was $0.00.

The historical rank and industry rank for Calithera Biosciences's 3-Year Dividend Growth Rate or its related term are showing as below:

CALA's 3-Year Dividend Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 14.5
* Ranked among companies with meaningful 3-Year Dividend Growth Rate only.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Calithera Biosciences's Dividend Payout Ratio for the three months ended in Dec. 2022 was 0.00. As of today, Calithera Biosciences's Dividend Yield % is 0.00%.

For more information regarding to dividend, please check our Dividend Page.


Competitive Comparison of Calithera Biosciences's 3-Year Dividend Growth Rate

For the Biotechnology subindustry, Calithera Biosciences's 3-Year Dividend Growth Rate, along with its competitors' market caps and 3-Year Dividend Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Calithera Biosciences's 3-Year Dividend Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Calithera Biosciences's 3-Year Dividend Growth Rate distribution charts can be found below:

* The bar in red indicates where Calithera Biosciences's 3-Year Dividend Growth Rate falls into.



Calithera Biosciences 3-Year Dividend Growth Rate Calculation

This is the average annual rate that a company has been raising its dividends. The growth rate is calculated with expontential compound based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.


Calithera Biosciences  (OTCPK:CALA) 3-Year Dividend Growth Rate Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

Calithera Biosciences's Dividend Payout Ratio for the quarter that ended in Dec. 2022 is calculated as

Dividend Payout Ratio=Dividends per Share (Q: Dec. 2022 )/ EPS without NRI (Q: Dec. 2022 )
=0/ -1.485
=N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Calithera Biosciences 3-Year Dividend Growth Rate Related Terms>


Calithera Biosciences (Calithera Biosciences) Business Description

Traded in Other Exchanges
N/A
Address
343 Oyster Point Boulevard, Suite 200, South San Francisco, CA, USA, 94080
Calithera Biosciences Inc is a clinical-stage pharmaceutical company. The business activity of the firm functions through the region of the United States. It focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. Its product candidate is CB-839, an inhibitor of glutaminase for the treatment of solid tumors. Its other product candidate, CB-1158, is being developed for hematology and oncology indications.
Executives
Deepika Pakianathan director, 10 percent owner 160 BOVET ROAD, SUITE 408, C/O DELPHI VENTURES, SAN MATEO CA 94402
Takeda Ventures, Inc. 10 percent owner 9625 TOWNE CENTRE DRIVE, SAN DIEGO CA 92121
Keith Orford officer: SR. VP, CLINICAL DEVELOPMENT CALITHERA BIOSCIENCES, 343 OYSTER POINT BLVD, SUITE 200, SOUTH SAN FRANCISCO CA 94080
Jonathan G Drachman director 21823 30TH DRIVE SE, BOTHELL WA 98021
Susan Molineaux director, officer: PRESIDENT AND CEO C/O CALITHERA BIOSCIENCES, INC., 343 OYSTER POINT BLVD., SUITE 200, SOUTH SAN FRANCISCO CA 94080
Christopher Molineaux officer: SR. VP, DEVELOPMENT CALITHERA BIOSCIENCES, 343 OYSTER POINT, SUITE 200, SOUTH SAN FRANCISCO CA 94080
Emil Kuriakose officer: CHIEF MEDICAL OFFICER 343 OYSTER POINT BLVD, SUITE 200, SOUTH SAN FRANCISCO CA 94080
Millennium Pharmaceuticals Inc 10 percent owner 40 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Takeda Pharmaceutical Co Ltd 10 percent owner 1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU, TOKYO M0 103-8668
J. Scott Garland director 210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Biotechnology Value Fund L P other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Stephanie Wong officer: VP, FINANCE 343 OYSTER POINT BLVD #200, SOUTH SAN FRANCISCO CA 94080
Bvf Inc/il 10 percent owner 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Biotechnology Value Fund Ii Lp other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Mark N Lampert 10 percent owner 1 SANSOME ST, 30TH FL, SAN FRANCISCO CA 94104